Clinical Trials, Medicinal Product Licensing, and Early Patient Access Pathways
The UK formally left the EU on 31 January 2020, followed by an 11-month transition period which ended on 31 December 2020. On 01 January 2021, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) became a standalone national authority. However, as a result of the Northern Ireland protocol, Northern Ireland will continue to follow the EU regulatory framework.
The MHRA has released guidelines explaining how clinical trials, licensing of medicinal products, importing, and exporting will be regulated from 01 January 2021. The new MHRA guidelines remain closely aligned with the EU regulatory framework but include a number of changes. To help sponsors prepare for the changes, PRA’s Regulatory Strategy & Agency Liaison (RSAL) team have assessed the new MHRA guidelines and have highlighted the following major areas in this white paper:
- Clinical trials
- Pediatric investigation plans
- Licensing of medicinal products
- Early patient access
- Orphan medicinal products
- Importing and exporting
The RSAL team can advise and partner with sponsors throughout the new MHRA regulatory process, and we strongly encourage sponsors to pay close attention to the upcoming new guidance that will be released by the MHRA.
Starting with Status
Small and medium-sized enterprises (SMEs) are the backbone of Europe’s economy, representing 99% of all EU businesses. SMEs are often innovative…
MDR Impacts on EU Regulatory Labeling of Drug-Device Combination Products
In their latest whitepaper, PRA’s Global Regulatory Affairs division explores the impact of Medical Device Regulation (MDR) on EU regulatory labeling…
Plain Language Summaries - Keeping the End in Mind: Key Considerations for Creating Plain Language Summaries
Plain language summaries (PLS), also known as lay summaries and trial results summaries, educate participants and the public about clinical trial…